Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Company Drug

Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment

Fineline Cube Dec 13, 2022

China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...

Company Deals

Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M

Fineline Cube Dec 13, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...

Company Medical Device

Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia

Fineline Cube Dec 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...

Company Drug

Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting

Fineline Cube Dec 13, 2022

China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...

Company R&D

ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform

Fineline Cube Dec 13, 2022

Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...

Company Deals

Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...

Company Drug

JW Therapeutics Presents Carteyva Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...

Company Deals

4B Technologies Raises RMB 100M in Pre-Series B Financing Round

Fineline Cube Dec 13, 2022

China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...

Company Deals

Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share

Fineline Cube Dec 13, 2022

China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong...

Company Policy / Regulatory

Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling

Fineline Cube Dec 13, 2022

Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the...

Company Drug

Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...

Company Deals

HitGen and Nitrase Therapeutics Enter Research Agreement

Fineline Cube Dec 12, 2022

China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc....

Company Deals R&D

Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research

Fineline Cube Dec 12, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences...

Company Deals

Innoforce Partners with RNAimmune for mRNA Development and Production

Fineline Cube Dec 12, 2022

Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off...

Company Medical Device

NMPA Approves COVID-19 Antigen Detection Reagents from Four Companies

Fineline Cube Dec 12, 2022

The National Medical Products Administration (NMPA) announced the marketing approvals for COVID-19 antigen detection reagents...

Company Deals

Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics

Fineline Cube Dec 12, 2022

Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The...

Company Drug

Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review

Fineline Cube Dec 12, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...

Posts pagination

1 … 521 522 523 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.